62924-83-8

Basic information

• Product Name: N-ETHYL-O-METHOXYBENZYLAMINE
• Synonyms: N-ETHYL-O-METHOXYBENZYLAMINE;N-ETHYL-2-METHOXY-BENZENEMETHANAMINE;N-(2-methoxybenzyl)ethanamine(SALTDATA: HCl)
• CAS NO: 62924-83-8
• Molecular Formula: C₁₀H₁₅NO
• Molecular Weight: 165.23
• Mol File: 62924-83-8.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-ETHYL-O-METHOXYBENZYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-ETHYL-O-METHOXYBENZYLAMINE(62924-83-8)
• EPA Substance Registry System: N-ETHYL-O-METHOXYBENZYLAMINE(62924-83-8)

Safety Data

• Hazardous Substances Data: 62924-83-8(Hazardous Substances Data)

Upstream product

• 858798-38-6 N-ethyl-N-(2-methoxy-benzyl)-formamide 
• 75-04-7 ethylamine 
• 135-02-4 ortho-anisaldehyde 
• 21615-34-9 2-Methoxybenzoyl chloride 
• 90874-72-9 ethyl-(2-methoxy-benzyliden)-amine 
• 91341-99-0 N-Aethyl-2-methoxy-benzamid 
• 63452-53-9 N-acetyl-2-methoxybenzylamine 

Downstream Products

• 1439915-51-1 7-(3-(ethyl(2-methoxybenzyl)amino)propoxy)-3-(4-(3-(ethyl(2-methoxybenzyl)amino) propoxy)phenyl)-5-hydroxy-4H-chromen-4-one 
• 1439915-84-0 7-(4-(ethyl(2-methoxybenzyl)amino)butoxy)-3-(4-(4-(ethyl(2-methoxybenzyl)amino) butoxy)phenyl)-5-hydroxy-4H-chromen-4-one 
• 1439916-11-6 7-((6-(ethyl(2-methoxybenzyl)amino)hexyl)oxy)-3-(4-((6-(ethyl(2-methoxybenzyl)amino) hexyl)oxy)phenyl)-5-hydroxy-4H-chromen-4-one 
• 1439913-21-9 7-(4-(ethyl(2-methoxybenzyl)amino)butoxy)-5-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one 
• 1439913-41-3 7-((6-(ethyl(2-methoxybenzyl)amino)hexyl)oxy)-5-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one 
• 1439919-36-4 3-(4-(3-(ethyl(2-methoxybenzyl)amino)propoxy)phenyl)-5-hydroxy-7-(methoxymethoxy)-4H-chromen-4-one 
• 1439910-26-5 3-(4-(3-(ethyl(2-methoxybenzyl)amino)propoxy)phenyl)-5,7-dihydroxy-4H-chromen-4-one 
• 1439919-61-5 3-(4-(4-(ethyl(2-methoxybenzyl)amino)butoxy)phenyl)-5-hydroxy-7-(methoxymethoxy)-4H-chromen-4-one 
• 1439910-53-8 3-(4-(4-(ethyl(2-methoxybenzyl)amino)butoxy)phenyl)-5,7-dihydroxy-4H-chromen-4-one 
• 1439919-88-6 3-(4-((6-(ethyl(2-methoxybenzyl)amino)hexyl)oxy)phenyl)-5-hydroxy-7-(methoxy methoxy)-4H-chromen-4-one 
• 1439912-99-8 7-(3-(ethyl(2-methoxybenzyl)amino)propoxy)-5-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one 

Relevant articles and documents

Design, synthesis and evaluation of novel dimethylamino chalcone-O-alkylamines derivatives as potential multifunctional agents against Alzheimer's disease

A novel series of dimethylamino chalcone-O-alkylamines derivatives was designed and synthesized as multifunctional agents for the treatment of AD. All the target compounds exhibited significant abilities to inhibit and disaggregate Aβ aggregation, and acted as potential selective AChE inhibitors, biometal chelators and selective MAO-B inhibitors. Among these compounds, compound TM-6 showed the greatest inhibitory activity against self-induced Aβ aggregation (IC50 = 0.88 μM) and well disaggregation ability toward self-induced Aβ aggregation (95.1%, 25 μM), the TEM images, molecular docking study and molecular dynamics simulations provided reasonable explanation for its high efficiency, and it was also found to be a remarkable antioxidant (ORAC-FL values of 2.1eq.), the best AChE inhibitor (IC50 = 0.13 μM) and MAO-B inhibitor (IC50 = 1.0 μM), as well as a good neuroprotectant. UV–visual spectrometry and ThT fluorescence assay revealed that compound TM-6 was not only a good biometal chelator by inhibiting Cu2+-induced Aβ aggregation (95.3%, 25 μM) but also could disassemble the well-structured Aβ fibrils (88.1%, 25 μM). Further, TM-6 could cross the blood-brain barrier (BBB) in vitro. More importantly, compound TM-6 did not show any acute toxicity in mice at doses of up to 1000 mg/kg and improved scopolamine-induced memory impairment. Taken together, these data indicated that TM-6, an excellent balanced multifunctional inhibitor, was a potential lead compound for the treatment of AD.

Design, synthesis and evaluation of novel ferulic acid-memoquin hybrids as potential multifunctional agents for the treatment of Alzheimer's disease

A novel series of ferulic acid-memoquin hybrids were designed, synthesized and evaluated as multifunctional agents for the treatment of Alzheimer's disease (AD). The in vitro studies showed that most of the compounds exhibited a significant ability to inhibit acetylcholinesterase (AChE) (IC50 of 3.2-34.7 μM) and self-induced β-amyloid (Aβ1-42) aggregation (30.8-39.1%, 25 μM), to act as potential antioxidants (ORAC-FL value of 0.9-1.3). In particular, compound 17d had the greatest ability to inhibit AChE (IC50 = 3.2 μM), and Aβ1-42 aggregation (30.8%) was also an excellent antioxidant and neuroprotectant. Moreover, it is capable of disaggregating self-induced Aβ aggregation. Furthermore, 17d could cross the blood-brain barrier (BBB) in vitro. The results showed that compound 17d is a potential multifunctional agent for the treatment of AD.

Design, synthesis and evaluation of genistein-O-alkylbenzylamines as potential multifunctional agents for the treatment of Alzheimer's disease

A series of genistein derivatives with carbon spacer-linked alkylbenzylamines were designed, synthesized and tested as multifunctional agents for the treatment of Alzheimer's disease (AD). The results showed that most of these compounds exhibited good acetylcholinesterase (AChE) inhibitory activity, with moderate-to-good anti-oxidative activity. Specifically, compounds 10b, 19d and 25d exhibited significant inhibition of β-amyloid (Aβ) aggregation and exhibited metal chelating properties. In particular, 25d inhibited: self-induced Aβ1-42 aggregation, Cu 2+-induced Aβ1-42 aggregation, and human AChE-induced Aβ1-40 aggregation by 35%, 77.8%, and 36.2%, respectively. Moreover, both kinetic analysis of AChE inhibition and the molecular modeling study suggested that 25d binds simultaneously to catalytic active site and peripheral anionic site of AChE. More importantly, compound 25d disassembled the well-structured Aβ fibrils generated by Cu2+-induced Aβ aggregation by 72.1%. Furthermore, the step-down passive avoidance test showed this compound significantly reversed scopolamine-induced memory deficit in mice. These results suggest that 25d may be a promising multifunctional agent for AD treatment.